drugset / Trial / NCT00594945

Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures

NCT00594945

Phase 2 Completed 45 enrolled Jazz Pharmaceuticals
Non-randomizedCrossoverOpen-labelTreatment

Summary

Evaluate the safety and efficacy of intranasal Clonazepam in subjects with epilepsy.

Timeline

Start
2007-12
Primary completion
2008-12
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Clonazepam Small molecule 2 mg Intranasal
Subject Clonazepam Small molecule 3 mg Intranasal

Indications